The PREvention Program for Alzheimer's RElated Delirium (PREPARED) cluster randomized trial: a study protocol.

Delirium Delirium superimposed on dementia Long-term care Modifiable risk factors Multicomponent intervention Nursing

Journal

BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548

Informations de publication

Date de publication:
16 11 2021
Historique:
received: 28 07 2021
accepted: 15 10 2021
entrez: 17 11 2021
pubmed: 18 11 2021
medline: 24 11 2021
Statut: epublish

Résumé

Delirium is a significant cause of morbidity and mortality among older people admitted to both acute and long-term care facilities (LTCFs). Multicomponent interventions have been shown to reduce delirium incidence in the acute care setting (30-73%) by acting on modifiable risk factors. Little work, however, has focused on using this approach to reduce delirium incidence in LTCFs. The objective is to assess the effectiveness of the multicomponent PREPARED Trial intervention in reducing the following primary outcomes: incidence, severity, duration, and frequency of delirium episodes in cognitively impaired residents. This 4-year, parallel-design, cluster randomized study will involve nursing staff and residents in 45-50 LTCFs in Montreal, Canada. Participating public and private LTCFs (clusters) that provide 24-h nursing care will be assigned to either the PREPARED Trial intervention or the control (usual care) arm of the study using a covariate constrained randomization procedure. Approximately 400-600 LTC residents aged 65 and older with dementia and/or cognitive impairment will be enrolled in the study and followed for 18 weeks. Residents must be at risk of delirium, delirium-free at baseline and have resided at the facility for at least 2 weeks. Residents who are unable to communicate verbally, have a history of specific psychiatric conditions, or are receiving end-of-life care will be excluded. The PREPARED Trial intervention consists of four main components: a decision tree, an instruction manual, a training package, and a toolkit. Primary study outcomes will be assessed weekly. Functional autonomy and cognitive levels will be assessed at the beginning and end of follow-up, while information pertaining to modifiable delirium risk factors, medical consultations, and facility transfers will be collected retrospectively for the duration of the follow-up period. Primary outcomes will be reported at the level of intervention assignment. All researchers analyzing the data will be blinded to group allocation. This large-scale intervention study will contribute significantly to the development of evidence-based clinical guidelines for delirium prevention in this frail elderly population, as it will be the first to evaluate the efficacy of a multicomponent delirium prevention program translated into LTC clinical practice on a large scale. NCT03718156 , ClinicalTrials.gov .

Sections du résumé

BACKGROUND
Delirium is a significant cause of morbidity and mortality among older people admitted to both acute and long-term care facilities (LTCFs). Multicomponent interventions have been shown to reduce delirium incidence in the acute care setting (30-73%) by acting on modifiable risk factors. Little work, however, has focused on using this approach to reduce delirium incidence in LTCFs.
METHODS
The objective is to assess the effectiveness of the multicomponent PREPARED Trial intervention in reducing the following primary outcomes: incidence, severity, duration, and frequency of delirium episodes in cognitively impaired residents. This 4-year, parallel-design, cluster randomized study will involve nursing staff and residents in 45-50 LTCFs in Montreal, Canada. Participating public and private LTCFs (clusters) that provide 24-h nursing care will be assigned to either the PREPARED Trial intervention or the control (usual care) arm of the study using a covariate constrained randomization procedure. Approximately 400-600 LTC residents aged 65 and older with dementia and/or cognitive impairment will be enrolled in the study and followed for 18 weeks. Residents must be at risk of delirium, delirium-free at baseline and have resided at the facility for at least 2 weeks. Residents who are unable to communicate verbally, have a history of specific psychiatric conditions, or are receiving end-of-life care will be excluded. The PREPARED Trial intervention consists of four main components: a decision tree, an instruction manual, a training package, and a toolkit. Primary study outcomes will be assessed weekly. Functional autonomy and cognitive levels will be assessed at the beginning and end of follow-up, while information pertaining to modifiable delirium risk factors, medical consultations, and facility transfers will be collected retrospectively for the duration of the follow-up period. Primary outcomes will be reported at the level of intervention assignment. All researchers analyzing the data will be blinded to group allocation.
DISCUSSION
This large-scale intervention study will contribute significantly to the development of evidence-based clinical guidelines for delirium prevention in this frail elderly population, as it will be the first to evaluate the efficacy of a multicomponent delirium prevention program translated into LTC clinical practice on a large scale.
TRIAL REGISTRATION
NCT03718156 , ClinicalTrials.gov .

Identifiants

pubmed: 34784897
doi: 10.1186/s12877-021-02558-3
pii: 10.1186/s12877-021-02558-3
pmc: PMC8594158
doi:

Banques de données

ClinicalTrials.gov
['NCT03718156']

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

645

Subventions

Organisme : CIHR
ID : PJT-148937
Pays : Canada

Informations de copyright

© 2021. The Author(s).

Références

N Engl J Med. 1999 Mar 4;340(9):669-76
pubmed: 10053175
BMC Geriatr. 2005 Mar 17;5:5
pubmed: 15774005
BMC Geriatr. 2018 Feb 2;18(1):39
pubmed: 29394886
Am J Epidemiol. 2008 Sep 15;168(6):656-64
pubmed: 18682488
J Am Med Dir Assoc. 2014 Jan;15(1):77.e1-9
pubmed: 24094898
J Nurs Res. 2015 Dec;23(4):322-9
pubmed: 26562464
J Am Geriatr Soc. 2009 Nov;57(11):2029-36
pubmed: 19754498
J Multidiscip Healthc. 2010 Jun 01;3:33-47
pubmed: 21197354
JAMA Intern Med. 2015 Apr;175(4):512-20
pubmed: 25643002
Ann Intern Med. 1990 Dec 15;113(12):941-8
pubmed: 2240918
Clin Nurs Res. 2009 May;18(2):153-71
pubmed: 19377042
Nat Rev Neurol. 2009 Apr;5(4):210-20
pubmed: 19347026
J Am Geriatr Soc. 1994 Aug;42(8):809-15
pubmed: 8046190
J Neurosci Nurs. 2006 Apr;38(2):90-101
pubmed: 16681289
J Am Geriatr Soc. 2005 May;53(5):871-4
pubmed: 15877567
J Am Board Fam Med. 2015 Sep-Oct;28(5):663-72
pubmed: 26355139
J Am Geriatr Soc. 2020 Oct;68(10):2329-2335
pubmed: 32710658
BMC Nurs. 2008 Feb 26;7:4
pubmed: 18302791
Clin Trials. 2004;1(3):297-305
pubmed: 16279255
Int J Epidemiol. 2015 Jun;44(3):1051-67
pubmed: 26174515
Int J Geriatr Psychiatry. 2012 Oct;27(10):999-1007
pubmed: 22367973
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
Ann Intern Med. 2008 Feb 19;148(4):295-309
pubmed: 18283207
Q J Exp Psychol. 1968 Aug;20(3):241-8
pubmed: 5683763
Curr Opin Psychiatry. 2010 May;23(3):250-4
pubmed: 20224406
Cochrane Database Syst Rev. 2014 Jan 31;(1):CD009537
pubmed: 24488526
J Clin Pharmacol. 2006 Dec;46(12):1481-6
pubmed: 17101747
Health Policy. 2006 Dec;79(2-3):175-94
pubmed: 16430989
J Frailty Aging. 2012;1(1):8-12
pubmed: 27092931
Ann Intern Med. 2013 Mar 5;158(5 Pt 2):375-80
pubmed: 23460093
Ann Intern Med. 2011 Jun 7;154(11):746-51
pubmed: 21646557
J Am Geriatr Soc. 2002 Oct;50(10):1723-32
pubmed: 12366629
Am J Public Health. 1982 Dec;72(12):1373-9
pubmed: 6814269
Psychosomatics. 1987 Jun;28(6):298-301, 304
pubmed: 3432545
Rev Med Interne. 2007 Sep;28(9):589-93
pubmed: 17512095
J Geriatr Psychiatry Neurol. 2017 Mar;30(2):104-108
pubmed: 28013571
Int J Geriatr Psychiatry. 2000 Nov;15(11):1021-7
pubmed: 11113982
J Am Geriatr Soc. 2005 Apr;53(4):622-8
pubmed: 15817008
J Am Geriatr Soc. 2004 Nov;52(11):1875-82
pubmed: 15507065
J Am Geriatr Soc. 2008 May;56(5):823-30
pubmed: 18384586
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Contemp Clin Trials. 2009 Mar;30(2):129-32
pubmed: 18977314
Int J Geriatr Psychiatry. 2013 Feb;28(2):127-34
pubmed: 22513757
J Am Geriatr Soc. 2003 Oct;51(10):1451-4
pubmed: 14511167
J Am Geriatr Soc. 2004 Oct;52(10):1744-9
pubmed: 15450055
J Am Geriatr Soc. 2001 Oct;49(10):1327-34
pubmed: 11890491
BMJ. 2012 Sep 04;345:e5661
pubmed: 22951546
Age Ageing. 2015 Mar;44(2):196-204
pubmed: 25424450
J Am Geriatr Soc. 2002 Dec;50(12):2101-3
pubmed: 12473034
J Am Med Dir Assoc. 2015 Jan;16(1):37-40
pubmed: 25239018
BMC Nurs. 2015 Apr 01;14:19
pubmed: 25844067
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2015;22(4):413-37
pubmed: 25325767
J Am Geriatr Soc. 2005 Mar;53(3):405-9
pubmed: 15743281
Int J Geriatr Psychiatry. 2011 Nov;26(11):1152-61
pubmed: 21274904
Q J Exp Psychol A. 2005 Jan;58(1):22-33
pubmed: 15881289
Arch Intern Med. 2007 Aug 13-27;167(15):1629-34
pubmed: 17698685
Acta Otolaryngol Suppl. 1990;476:167-75; discussion 176
pubmed: 2087959
Age Ageing. 2002 Jul;31(4):277-85
pubmed: 12147566
J Gen Intern Med. 1998 Mar;13(3):204-12
pubmed: 9541379
Int J Geriatr Psychiatry. 2001 Apr;16(4):349-55
pubmed: 11333420
Clin Trials. 2005;2(2):99-107
pubmed: 16279131
J Am Med Dir Assoc. 2009 Mar;10(3):181-8
pubmed: 19233058

Auteurs

Machelle Wilchesky (M)

Centre for Research in Aging, Donald Berman Maimonides Geriatric Centre, 5795 Ave Caldwell, Montreal, QC, H4W 1W3, Canada. machelle.wilchesky@mcgill.ca.
Department of Family Medicine, McGill University, 5858 Côte-des-Neiges Road, Montreal, QC, H3S 1Z1, Canada. machelle.wilchesky@mcgill.ca.
Division of Geriatric Medicine, McGill University, Jewish General Hospital, 3755 Cote St. Catherine Road, Room E-0012, Montreal, QC, H3T 1E2, Canada. machelle.wilchesky@mcgill.ca.
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Cote St. Catherine Road, Montreal, QC, H3T 1E2, Canada. machelle.wilchesky@mcgill.ca.

Stephanie A Ballard (SA)

Centre for Research in Aging, Donald Berman Maimonides Geriatric Centre, 5795 Ave Caldwell, Montreal, QC, H4W 1W3, Canada.
Department of Family Medicine, McGill University, 5858 Côte-des-Neiges Road, Montreal, QC, H3S 1Z1, Canada.

Philippe Voyer (P)

Faculty of Nursing Sciences, Laval University, Pavillon Ferdinand-Vandry, 1050 avenue de la Médecine, local 3645, Québec, QC, G1V 0A6, Canada.
Centre d'excellence sur le vieillissement de Québec, Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale, 1050 chemin Sainte-Foy, L2-30, Quebec City, QC, G1S 4L8, Canada.

Jane McCusker (J)

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Ave W, Montreal, QC, H3A 1A2, Canada.
St. Mary's Research Centre, 3830 Avenue Lacombe, Hayes Pavilion, suite 4720, Montreal, QC, H3T 1M5, Canada.

Ovidiu Lungu (O)

Centre for Research in Aging, Donald Berman Maimonides Geriatric Centre, 5795 Ave Caldwell, Montreal, QC, H4W 1W3, Canada.
Functional Neuroimaging Unit, Centre de recherche de l'Institut universitaire de gériatrie de Montréal, 4565 Queen Mary Rd, Montreal, QC, H3W 1W5, Canada.
Department of Psychiatry, Université de Montréal, Pavillon Roger-Gaudry, Faculté de Medicine, C.P. 6128, succursale Centre-ville, Montreal, QC, H3C 3J7, Canada.

Nathalie Champoux (N)

Faculty of Medicine, Université de Montréal, 2900 Boulevard Edouard-Montpetit, Montreal, QC, H3T 1J4, Canada.

T T Minh Vu (TTM)

Centre de recherche du CHUM, 91000, rue Saint-Denis, Montréal, QC, H2X 0A9, Canada.

Martin G Cole (MG)

Department of Psychiatry, McGill University, Ludmer Research & Training Building, 1033 Pine Avenue West, Montreal, QC, H3A 1A, Canada.

Johanne Monette (J)

Division of Geriatric Medicine, McGill University, Jewish General Hospital, 3755 Cote St. Catherine Road, Room E-0012, Montreal, QC, H3T 1E2, Canada.

Antonio Ciampi (A)

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Ave W, Montreal, QC, H3A 1A2, Canada.
St. Mary's Research Centre, 3830 Avenue Lacombe, Hayes Pavilion, suite 4720, Montreal, QC, H3T 1M5, Canada.

Eric Belzile (E)

St. Mary's Research Centre, 3830 Avenue Lacombe, Hayes Pavilion, suite 4720, Montreal, QC, H3T 1M5, Canada.

Pierre-Hugues Carmichael (PH)

Centre d'excellence sur le vieillissement de Québec, Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale, 1050 chemin Sainte-Foy, L2-30, Quebec City, QC, G1S 4L8, Canada.

Ted McConnell (T)

Division of General Internal Medicine, McGill University, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH